Pricing Log in Create free account

Apollomics Inc. (APLM) vs Kalaris Therapeutics Inc. (KLRS)

Apollomics Inc. and Kalaris Therapeutics Inc. are both Biotechnology companies. Apollomics Inc. and Kalaris Therapeutics Inc. are of similar size ($51.6M and $49.5M). Across the 7 metrics below, Apollomics Inc. leads on 5 and Kalaris Therapeutics Inc. on 2.

Valuation

Metric APLM KLRS Biotechnology median
P/E n/m n/m 10.60
P/S — n/m 9.40
P/B n/m 1.01 2.13
Price to free cash flow n/m n/m 25.18
EV/EBITDA n/m 0.33 0.66
EV/Sales n/m n/m 9.02
Earnings yield (0.32%) (85.64%) (32.88%)
Free cash flow yield 0.00% (70.40%) (23.13%)

Profitability

Metric APLM KLRS Biotechnology median
Gross margin — 0.00% 68.51%
Operating margin — 0.00% 0.00%
Net margin 0.00% 0.00% 0.00%
Free cash flow margin 0.00% 0.00% 0.00%
Return on equity 0.00% (79.91%) (51.96%)
Return on assets 0.00% (46.02%) (46.06%)
Return on invested capital 0.00% 0.00% 0.00%

Growth

Metric APLM KLRS Biotechnology median
Revenue growth (TTM) — — 6.76%
EPS growth (last fiscal year) 85.66% 94.50% 29.88%
Revenue growth, 5-year CAGR 32.77% — 9.75%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric APLM KLRS Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 0.96 10.98 4.97
Net debt to EBITDA 0.37 2.54 1.01

Dividend

Metric APLM KLRS Biotechnology median
Dividend yield — — 0.41%
Payout ratio — — —

Size

Metric APLM KLRS Biotechnology median
Market cap 49.49m 51.55m 161.82m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack